Kidney Transplant x2 & Killing It! Nephrologist: “We have to look at TRT for our other patients!”

An older male patient describes severe kidney decline that began during an illness overseas. Early clinic visits showed blood pressure off the chart while symptoms were minimized. Motrin was given despite hypertension, and the kidneys were already deteriorating quickly. Creatinine is recalled as reaching about eleven during repeated visits for worsening symptoms. Emergency dialysis began through the leg, and evacuation planning became a life critical priority. Medical teams warned dialysis had to resume within hours to prevent a fatal outcome. A stressful transport back to the United States is described as the turning point toward stabilization.

Earlier doctors discussed a rare diagnosis linked to a strep infection and glomerular inflammation. Post streptococcal glomerulonephritis is mentioned as the likely explanation for the initial collapse. Years of dialysis followed, and the first transplant wait is described as long and exhausting. A live donor match led to a transplant on October second, two thousand one. That first transplanted kidney is described as lasting about eighteen years. Return to dialysis occurred later, and a second live donor opportunity arrived unexpectedly. Two separate transplant experiences are framed as proof that persistent advocacy can save lives.

Chronic kidney disease can persist even after transplantation, and anemia is discussed as common. Low hemoglobin is linked to reduced erythropoietin signaling from impaired kidney function. EPO therapy is described as heavily used, with later regulation changes affecting dosing. Low testosterone is also discussed, with levels described around two hundred fifty to three hundred. Testosterone support is presented as restoring function and improving overall quality of life. A nephrologist argues that other dialysis and transplant patients may benefit from similar evaluation. The closing message stresses monitoring, shared decision making, and honest risk discussions with clinicians.